GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York

Annual General Meeting on June 11, 2019

GenSight Biologics reports positive 96-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

GenSight Biologics Announces the Filing of its 2018 Annual Financial Report

GenSight Biologics announces presentation of 72-week data from the REVERSE & RESCUE Phase III trials of GS010 at the Annual Meeting of ARVO